Australian Paediatric Surveillance Unit (APSU) Annual Surveillance Report 2022

Authors

  • Suzy M Teutsch The Australian Paediatric Surveillance Unit;The University of Sydney, Faculty of Medicine and Health, Discipline of Child and Adolescent Health, Sydney, New South Wales, Australia; The Sydney Children’s Hospitals Network, Westmead, Sydney, New South Wales, Australia
  • Carlos A Nunez The Australian Paediatric Surveillance Unit;The University of Sydney, Faculty of Medicine and Health, Discipline of Child and Adolescent Health, Sydney, New South Wales, Australia; The Sydney Children’s Hospitals Network, Westmead, Sydney, New South Wales, Australia
  • Anne Morris The Australian Paediatric Surveillance Unit;The University of Sydney, Faculty of Medicine and Health, Discipline of Child and Adolescent Health, Sydney, New South Wales, Australia; The Sydney Children’s Hospitals Network, Westmead, Sydney, New South Wales, Australia
  • Guy D Eslick The Australian Paediatric Surveillance Unit;The University of Sydney, Faculty of Medicine and Health, Discipline of Child and Adolescent Health, Sydney, New South Wales, Australia; The Sydney Children’s Hospitals Network, Westmead, Sydney, New South Wales, Australia
  • Elizabeth J Elliott The University of Sydney, Faculty of Medicine and Health, Discipline of Child and Adolescent Health, Sydney, New South Wales, Australia; The Sydney Children’s Hospitals Network, Westmead, Sydney, New South Wales, Australia; Director of the Australian Paediatric Surveillance Unit

DOI:

https://doi.org/10.33321/cdi.2023.47.46

Keywords:

Australia, child, communicable disease, emerging infectious diseases, public health surveillance, rare disease

Abstract

For 30 years the Australian Paediatric Surveillance Unit (APSU) has conducted national surveillance of rare communicable diseases and rare complications of communicable diseases. In this report, we describe the results of thirteen such studies surveyed by the APSU in 2022, including reported case numbers and incidence estimates, demographics, clinical features, management and short-term outcomes. Conditions described are: acute flaccid paralysis (AFP); congenital cytomegalovirus (cCMV); neonatal and infant herpes simplex virus (HSV) infection; perinatal exposure to human immunodeficiency virus (HIV) and paediatric HIV infection; severe complications of influenza; juvenile-onset recurrent respiratory papillomatosis (JoRRP); congenital rubella infection/syndrome; congenital varicella syndrome (CVS) and neonatal varicella infection (NVI); and the new conditions dengue; Q fever; and severe acute hepatitis. In 2022, cases of severe complications of influenza were reported to the APSU for the first time since 2019. This likely reflects the easing of government-mandated restrictions imposed in 2020–2021 to curb the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the re-emergence of a range of infectious diseases. As previously, AFP surveillance by the APSU contributed to Australia achieving a minimum target incidence of one AFP case per 105 children aged less than 15 years. Cases of JoRRP and NVI were reported in 2022. This indicates potential gaps in human papillomavirus (HPV) and varicella vaccination coverage respectively, especially in high-risk groups such as young migrant and refugee women of childbearing age from countries without universal vaccination programs. Paediatric HIV case numbers resulting from mother-to-child-transmission (MTCT) of HIV remain low in Australia due to use of effective intervention strategies. However, there has been an increase in the number of imported cases of HIV in children (mainly perinatally-acquired) from countries with a high HIV prevalence. Without effective vaccines, there has been no decline in the incidence of congenital CMV and neonatal HSV, indicating the importance of early identification and management to reduce morbidity and mortality. The first cases of dengue, Q fever and severe acute hepatitis were received by APSU in 2022, including two cases of acute hepatitis in which aetiology has not been confirmed to date. The APSU has an important ongoing role in monitoring rare childhood infections.

Downloads

Download data is not yet available.

References

Williams K, Elliott E. Role of the Australian Paediatric Surveillance Unit in monitoring communicable diseases of childhood. Commun Dis Intell. 1998;22(13);283–7.

Teutsch SM, Nunez CN, Morris A, Eslick GD, Berkhout A, Novakovic D et al. Australian Paediatric Surveillance Unit (APSU) Annual Surveillance Report 2021. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.66.

Teutsch SM, Nunez CA, Morris A, Eslick GD, Khandaker G, Berkhout A et al. Australian Paediatric Surveillance Unit (APSU) Annual Surveillance Report 2020. Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.59.

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. doi: https//doi.org/10.1016/j.jbi.2008.08.010.

Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: https://doi.org/10.1016/j.jbi.2019.103208.

Australian Bureau of Statistics. National, state and territory population. Reference period: September 2022. [Webpage.] Canberra: Australian Bureau of Statistics; 16 March 2023. [Accessed on 24 March 2023.] Available from: https://www.abs.gov.au/statistics/people/population/national-state-and-territory-population/latest-release.

Australian Institute of Health and Welfare (AIHW). Australia’s mothers and babies. Canberra: Australian Government, AIHW; 14 December 2022. [Accessed on 24 March 2023.] Available from: https://www.aihw.gov.au/reports/mothers-babies/australias-mothers-babies/contents/about.

World Health Organization (WHO). Major milestone reached in global polio eradication: Western Pacific Region is certified polio-free. Commun Dis Intell. 2000;24(10):304.

Zurynski Y, Davey E, Elliott EJ. Australian Paediatric Surveillance Unit annual report, 2008 and 2009. Commun Dis Intell Q Rep. 2010;34(3):285–90.

Kidd S, Lopez A, Nix WA, Anyalechi G, Itoh M, Yee E et al. Vital Signs: clinical characteristics of patients with confirmed acute flaccid myelitis, United States, 2018. MMWR Morb Mortal Wkly Rep. 2020;69(31):1031–8. doi: https://doi.org/10.15585/mmwr.mm6931e3.

Bao J, Nunez C, Elliott E, Dinsmore N, McRae J, Morris A et al. Acute flaccid paralysis in Australian children from 2007 to 2017: clinical spectrum and epidemiology. Neuroepidemiology. 2023;57(1):25–34. doi: https://doi.org/10.1159/000528293.

Kaye M, Garcia-Clapes A, Hobday LK, Ibrahim A, Chanthalavanh P, Bruggink L et al. Australian National Enterovirus Reference Laboratory annual report, 2021. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.55.

WHO Regional Office for the Western Pacific (WPRO). Polio Bulletin 2022. [Webpage.] Manila: WHO WPRO; 2022. Available from: https://apps.who.int/iris/handle/10665/350978.

WHO WPRO. Twenty-eighth Meeting of the Regional Commission for the Certification of Poliomyelitis Eradication in the Western Pacific, Hanoi, Viet Nam, 15-17 November 2022: meeting report. Manila: WHO WPRO; 2022. Available from: https://apps.who.int/iris/handle/10665/366288.

Munro SC, Trincado D, Hall B, Rawlinson WD. Symptomatic infant characteristics of congenital cytomegalovirus disease in Australia. J Paediatr Child Health. 2005;41(8):449–52. doi: https://doi.org/10.1111/j.1440-1754.2005.00665.x.

Rawlinson WD, Boppana SB, Fowler KB, Kimberlin DW, Lazzarotto T, Alain S et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017;17(6):e177–88. doi: https://doi.org/10.1016/S1473-3099(17)30143-3.

Poole CL, Kimberlin DW. Antiviral drugs in newborn and children. Pediatr Clin North Am. 2017;64(6):1403–15. doi: https://doi.org/10.1016/j.pcl.2017.08.014.

Reid A, Bowen AC, Brennan-Jones CG, Kuthubutheen JB. Congenital cytomegalovirus: the case for targeted infant screening in Australia. Med J Aust. 2022;216(4):167–71. doi: https://doi.org/10.5694/mja2.51406.

McMullan BJ, Palasanthiran P, Jones CA, Hall BM, Robertson PW, Howard J et al. Congenital cytomegalovirus--time to diagnosis, management and clinical sequelae in Australia: opportunities for earlier identification. Med J Aust. 2011;194(12):625–9. doi: https://doi.org/10.5694/j.1326-5377.2011.tb03144.x.

Garland S, Jones C, Palasanthiran P. Cytomegalovirus. In Palasanthiran P, Starr M, Jones C, Giles M, eds. Management of perinatal infections (3rd edition). Sydney: Australasian Society for Infectious Diseases (ASID), 2022;9–14.

Jones CA, Greenow-Raynes C, Isaacs D, Neonatal HSV Study Investigators and Contributors to the APSU. Population-based surveillance of neonatal herpes simplex virus infection in Australia, 1997–2011. Clin Infect Dis. 2014;59(4):525–31. doi: https://doi.org/10.1093/cid/ciu381.

Teutsch S, Zurynski Y, Elliott E, chief investigators of APSU surveillance studies. Australian Paediatric Surveillance Unit Annual Report, 2017. Commun Dis Intell (2018). 2018;42:S2209-6051(18)00006-4.

Teutsch S, Berkhout A, Raynes-Greenow C, Zurynski Y, Britton PN, Jones CA. Characteristics of neonatal herpes simplex central nervous system disease in Australia (1997–2020). J Clin Virol. 2023;165:105526. doi: https://doi.org/10.1016/j.jcv.2023.105526.

Jones C. Herpes simplex virus. In Palasanthiran P, Starr M, Jones C, Giles M, eds. Management of perinatal infections (3rd edition). Sydney: ASID, 2022;37–42.

McDonald AM, Cruickshank M, Ziegler JB, Elliott E, Kaldor JM. Perinatal exposure to HIV in Australia, 1982–1994. Med J Aust. 1997;166(2):77–80. doi: https://doi.org/10.5694/j.1326-5377.1997.tb138725.x.

Teutsch SM, Nunez CA, Morris A, McGregor S, King J, Brotherton JML et al. Australian Paediatric Surveillance Unit (APSU) annual surveillance report 2019. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.60.

Teutsch S, Zurynski Y, Elliott E, chief investigators of APSU surveillance studies. Australian Paediatric Surveillance Unit annual report, 2017. Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00006-4.

Palasanthiran P. Human Immunodeficiency virus. In Palasanthiran P, Starr M, Jones C, Giles M, eds. Management of perinatal infections (3rd edition). Sydney: ASID, 2022;43–50.

Deverell M, Phu A, Zurynski YA, Elliott EJ, all chief investigators of APSU surveillance studies. Australian Paediatric Surveillance Unit annual report, 2014. Commun Dis Intell Q Rep. 2016;40(2):E216–20.

King J, McManus H, Kwon A, Gray R, McGregor S. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual surveillance report 2022. Sydney: The Kirby Institute, University of New South Wales; 2022. [Accessed on 24 March 2023.] doi: http://doi.org/10.26190/sx44-5366.

Teutsch SM, Zurynski YA, Nunez C, Lester-Smith D, Festa M, Booy R et al. Ten years of national seasonal surveillance for severe complications of influenza in Australian children. Pediatr Infect Dis J. 2021;40(3):191–8. doi: https://doi.org/10.1097/INF.0000000000002961.

Donnelley E, Teutsch S, Zurynski Y, Nunez C, Khandaker G, Lester-Smith D et al. Severe influenza-associated neurological disease in Australian children: seasonal population-based surveillance 2008–2018. J Pediatric Infect Dis Soc. 2022;11(12):533–40. doi: https://doi.org/10.1093/jpids/piac069.

Novakovic D, Cheng ATL, Zurynski Y, Booy R, Walker PJ, Berkowitz R et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis. 2018;217(2):208–12. doi: https://doi.org/10.1093/infdis/jix498.

Somers GR, Tabrizi SN, Borg AJ, Garland SM, Chow CW. Juvenile laryngeal papillomatosis in a pediatric population: a clinicopathologic study. Pediatr Pathol Lab Med. 1997;17(1):53–64.

Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–8. doi: https://doi.org/10.1016/S1470-2045(05)70101-7.

Khandaker G, Zurynski Y, Jones C. Surveillance for congenital rubella in Australia since 1993: cases reported between 2004 and 2013. Vaccine. 2014;32(50):6746–51. doi: https://doi.org/10.1016/j.vaccine.2014.10.021.

Deverell M, Phu A, Zurynski YA, Elliott EJ, all chief investigators of APSU surveillance studies. Australian Paediatric Surveillance Unit annual report, 2015. Commun Dis Intell Q Rep. 2017;41(2):E181–5.

Sullivan EM, Burgess MA, Forrest JM. The epidemiology of rubella and congenital rubella in Australia, 1992 to 1997. Commun Dis Intell. 1999 Aug 5;23(8):209–14.

Khandaker G, Marshall H, Peadon E, Zurynski Y, Burgner D, Buttery J et al. Congenital and neonatal varicella: impact of the national varicella vaccination programme in Australia. Arch Dis Child. 2011;96(5):453–6. doi: https://doi.org/10.1136/adc.2010.206037.

Forrest J, Mego S, Burgess M. Congenital and neonatal varicella in Australia. J Paediatr Child Health. 2000;36(2):108–13. doi: https://doi.org/10.1046/j.1440-1754.2000.00474.x.

Teutsch S, Eslick GD, Morris A, Walker J, Al Imam MH, Khan A et al. Potential to prevent congenital and neonatal varicella infection in Australia through immigration screening and vaccination. (Abstract for the RACP Congress 2022, A Climate for Change,12–14 May 2022, Melbourne, Victoria, Australia and Online.) J Paediatr Child Health. 2022;58(S1):19. doi: https://doi.org/10.1111/jpc.24_15962.

Walker J, Teutsch S, Morris A, Eslick GD, Al Imam MH, Khan A et al. Active prospective national surveillance for congenital and neonatal varicella in Australia shows potential prevention opportunities. Vaccine X. 2023;13:100278. doi: https://doi.org/10.1016/j.jvacx.2023.100278.

Simmons CP, Farrar JJ, Nguyen vV, Wills B. Dengue. N Engl J Med. 2012;366(15):1423–32. doi: https://doi.org/10.1056/NEJMra1110265.

Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. Lancet. 2019;393(10169):350–63. doi: https://doi.org/10.1016/S0140-6736(18)32560-1.

Walker J, Pyke A, Florian P, Rodney Harris RM, Khandaker G. Re‐defining the dengue‐receptive area of Queensland after the 2019 dengue outbreak in Rockhampton. Med J Aust. 2021;215(4):182. doi: https://doi.org/10.5694/mja2.51151.

Wilder‐Smith A. The expanding geographic range of dengue in Australia. Med J Aust. 2021;215(4):171–2. doi: https://doi.org/10.5694/mja2.51185.

Wakimoto MD, Camacho LAB, Guaraldo L, Damasceno LS, Brasil P. Dengue in children: a systematic review of clinical and laboratory factors associated with severity. Expert Rev Anti Infect Ther. 2015;13(12):1441–56. doi: https://doi.org/10.1586/14787210.2015.1100534.

Wilder-Smith A, Vannice KS, Hombach J, Farrar J, Nolan T. Population perspectives and World Health Organization recommendations for CYD-TDV dengue vaccine. J Infect Dis. 2016;214(12):1796–9. doi: https://doi.org/10.1093/infdis/jiw341.

Wilder-Smith A. Dengue vaccine development: challenges and prospects. Curr Opin Infect Dis. 2022;35(5):390–6. doi: https://doi.org/10.1097/QCO.0000000000000871.

Maurin M, Raoult D. Q fever. Clin Microbiol Rev. 1999;12(4):518–53. doi: https://doi.org/10.1128/CMR.12.4.518.

Honarmand H. Q Fever: an old but still a poorly understood disease. Interdiscip Perspect Infect Dis. 2012;2012:131932. doi: https://doi.org/10.1155/2012/131932.

Sloan-Gardner TS, Massey PD, Hutchinson P, Knope K, Fearnley E. Trends and risk factors for human Q fever in Australia, 1991–2014. Epidemiol Infect. 2017;145(4):787–95. doi: https://doi.org/10.1017/S0950268816002843.

Tozer S, Wood C, Si D, Nissen M, Sloots T, Lambert S. The improving state of Q fever surveillance. A review of Queensland notifications, 2003–2017. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.48.

Gikas A, Kokkini S, Tsioutis C. Q fever: clinical manifestations and treatment. Expert Rev Anti Infect Ther. 2010;8(5):529–39. doi: https://doi.org/10.1586/eri.10.29.

Australian Government Department of Health and Aged Care. Q Fever – CDNA National Guidelines for Public Health Units. [Webpage.] Canberra: Australian Government Department of Health and Aged Care; 27 November 2018. Available from: https://www.health.gov.au/resources/publications/q-fever-cdna-national-guidelines-for-public-health-units.

Cherry CC, Kersh GJ. Pediatric Q fever. Curr Infect Dis Rep. 2020;22(4):10.1007/s11908-020-0719-0. doi: https://doi.org/10.1007/s11908-020-0719-0.

Eastwood K, Graves SR, Massey PD, Bosward K, van den Berg D, Hutchinson P. Q fever: a rural disease with potential urban consequences. Aust J Gen Pract. 2018;47(3):5555. doi: https://doi.org/10.31128/AFP-08-17-4299.

National Centre for Immunisation Research and Surveillance (NCIRS). Optimising Q fever vaccination in Australia: protecting our rural adolescents. [Internet.] Sydney: NCIRS; 23 July 2020. [Accessed on 2 October 2021.] Available from: https://www.ncirs.org.au/optimising-q-fever-vaccination-australia-protecting-our-rural-adolescents.

Marsh K, Tayler R, Pollock L, Roy K, Lakha F, Ho A et al. Investigation into cases of hepatitis of unknown aetiology among young children, Scotland, 1 January 2022 to 12 April 2022. Euro Surveill. 2022;27(15): 2200318. doi: https://doi.org/10.2807/1560-7917.ES.2022.27.15.2200318.

Cevik M, Rasmussen AL, Bogoch II, Kindrachuk J. Acute hepatitis of unknown origin in children. BMJ. 2022;377:o1197. doi: https://doi.org/10.1136/bmj.o1197.

WHO. Severe acute hepatitis of unknown aetiology in children - Multi-country. [Internet.] Geneva: WHO; 12 July 2022. [Accessed on 27 March 2023.] Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON400.

Nunez C, Morris A, Jones CA, Badawi N, Baynam G, Hansen M et al. Microcephaly in Australian children, 2016–2018: national surveillance study. Arch Dis Child. 2021;106(9):849–54. doi: https://doi.org/10.1136/archdischild-2020-320456.

Elliott EJ, Robins-Browne RM, O’Loughlin EV, Bennett-Wood V, Bourke J, Henning P et al. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child. 2001;85(2):125–31. doi: https://doi.org/10.1136/adc.85.2.125.

Zurynski YA, Lester-Smith D, Festa MS, Kesson AM, Booy R, Elliott EJ. Enhanced surveillance for serious complications of influenza in children: role of the Australian Paediatric Surveillance Unit. Commun Dis Intell Q Rep. 2008;32(1):71–6.

Goh AE, Choi EH, Chokephaibulkit K, Choudhury J, Kuter B, Lee PI et al. Burden of varicella in the Asia-Pacific region: a systematic literature review. Expert Rev Vaccines. 2019;18(5):475–93. doi: https://doi.org/10.1080/14760584.2019.1594781.

Ahn KH, Park YJ, Hong SC, Lee EH, Lee JS, Oh MJ et al. Congenital varicella syndrome: a systematic review. J Obstet Gynaecol. 2016;36(5):563–6. doi: https://doi.org/10.3109/01443615.2015.1127905.

Hamilton ST, van Zuylen W, Shand A, Scott GM, Naing Z, Hall B et al. Prevention of congenital cytomegalovirus complications by maternal and neonatal treatments: a systematic review. Rev Med Virol. 2014;24(6):420–33. doi: https://doi.org/10.1002/rmv.1814.

Zheng QY, Huynh KT, van Zuylen WJ, Craig ME, Rawlinson WD. Cytomegalovirus infection in day care centres: a systematic review and meta‐analysis of prevalence of infection in children. Rev Med Virol. 2019;29(1):e2011. doi: https://doi.org/10.1002/rmv.2011.

Vermillion MS, Klein SL. Pregnancy and infection: using disease pathogenesis to inform vaccine strategy. NPJ Vaccines. 2018;3(1):6. doi: https://doi.org/10.1038/s41541-017-0042-4.

Seib K, Pollard AJ, de Wals P, Andrews RM, Zhou F, Hatchett RJ et al. Policy making for vaccine use as a driver of vaccine innovation and development in the developed world. Vaccine. 2017;35(10):1380–9. doi: https://doi.org/10.1016/j.vaccine.2016.10.080.

Taylor L, Petousis-Harris H, Ellis T, Turner N, Nowlan M. 2012 Antigen Review: Varicella-zoster virus (chicken pox and shingles). Auckland: University of Auckland, Libraries and Learning Services (Te Tumu Herenga); July 2014. Available from: https://researchspace.auckland.ac.nz/handle/2292/47716.

Australian Government Department of Health and Aged Care. National 2022 Influenza Season Summary. Reporting period: 01 January to 09 October 2022. Canberra: Australian Government Department of Health and Aged Care; December 2022. [Accessed on 23 March 2023]. Available from: https://www.health.gov.au/sites/default/files/2022-12/aisr-2022-national-influenza-season-summary.pdf.

NCIRS. Significant events in influenza vaccination practice in Australia. Sydney: NCIRS; 2022. Available from: https://ncirs.org.au/sites/default/files/2022-11/Influenza-history-November%202022.pdf.

Hull B, Hendry A, Dey A, Brotherton J, Macartney K, Beard F. Annual Immunisation Coverage Report 2021. Commun Dis Intell (2018). 2023;47. In press.

NCIRS. Influenza vaccination coverage data. [Webpage.] Sydney: NCIRS; 2023. [Accessed on 24 March 2023.] Available from: https://ncirs.org.au/influenza-vaccination-coverage-data.

WHO. Polio eradication strategy 2022–2026: delivering on a promise. Geneva: WHO; 9 June 2021. [Accessed on 24 March 2023.] Available from: https://www.who.int/publications/i/item/9789240031937.

Australian Government Department of Health and Aged Care. HPV (human papillomavirus) vaccine. [Webpage.] Canberra: Australian Government Department of Health and Aged Care; 2023. [Accessed on 31 March 2023.] Available from: https://www.health.gov.au/topics/immunisation/vaccines/human-papillomavirus-hpv-immunisation-service.

Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17(5):355–63. doi: https://doi.org/10.1002/rmv.544.

Smithers-Sheedy H, Raynes-Greenow C, Badawi N, Fernandez MA, Kesson A, McIntyre S et al. Congenital cytomegalovirus among children with cerebral palsy. J Pediatr. 2017;181:267–71.e1. doi: https://doi.org/10.1016/j.jpeds.2016.10.024.

Samies NL, James SH. Prevention and treatment of neonatal herpes simplex virus infection. Antiviral Res. 2020;176:104721. doi: https://doi.org/10.1016/j.antiviral.2020.104721.

McGregor S, King J, McManus H, Gray R, Guy R. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: The Kirby Institute, University of New South Wales; 2018. [Accessed on 24 March 2023.] Available from: https://kirby.unsw.edu.au/report/asr2018.

WHO. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. Geneva: WHO; 2022. [Accessed on 24 March 2023.] Available from: https://www.who.int/publications/i/item/9789240053779.

Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–8. doi: https://doi.org/10.1016/S0140-6736(20)31094-1.

WHO. Multisystem inflammatory syndrome in children and adolescents with COVID-19. Geneva: WHO; 15 May 2020. [Accessed on 22 March 2023.] Available from: https://www.who.int/publications-detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19.

European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: paediatric inflammatory multisystem syndrome and SARS -CoV-2 infection in children. Solna: ECDC; 15 May 2020. [Accessed on 22 March 2023.] Available from: https://www.ecdc.europa.eu/en/publications-data/paediatric-inflammatory-multisystem-syndrome-and-sars-cov-2-rapid-risk-assessment.

Yakob L, Hu W, Frentiu FD, Gyawali N, Hugo LE, Johnson B et al. Japanese encephalitis emergence in Australia: the potential population at risk. Clin Infect Dis. 2023:76(2):335–7. doi: https://doi.org/10.1093/cid/ciac794.

Downloads

Additional Files

Published

24/08/23

How to Cite

Teutsch, Suzy M, Carlos A Nunez, Anne Morris, Guy D Eslick, and Elizabeth J Elliott. 2023. “Australian Paediatric Surveillance Unit (APSU) Annual Surveillance Report 2022”. Communicable Diseases Intelligence 47 (August). https://doi.org/10.33321/cdi.2023.47.46.

Issue

Vol. 47 (2023)

Section

Annual report

Categories

License

Copyright (c) 2023 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 > >>